Your email has been successfully added to our mailing list.

×
0.0517300445358 0.0517300445358 0.0517300445358 0.0517300445358 -0.0339157245632065 -0.0339157245632065 -0.0339157245632065 -0.0339157245632065
Stock impact report

Why Clinuvel Pharmaceuticals (ASX:CUV) Is Up 5.9% After Strong Earnings and NASDAQ ADR Expansion Plans – And What's Next [Yahoo! Finance]

CLINUVEL PHARMS LTD S/ADR (CLVLY) 
NASDAQ:AMEX Investor Relations: clinuvel.com/investors
Company Research Source: Yahoo! Finance
Clinuvel Pharmaceuticals recently reported full-year revenue of A$105.3 million and net income of A$36.17 million, declared its eighth consecutive annual dividend of A$0.05 per share, and affirmed plans for a Level II ADR listing on NASDAQ to boost U.S. investor visibility. Show less Read more
Impact Snapshot
Event Time:
CLVLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for CLVLY alerts
Opt-in for
CLVLY alerts

from News Quantified
Opt-in for
CLVLY alerts

from News Quantified